Compare EQH & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | ARWR |
|---|---|---|
| Founded | 1859 | 2003 |
| Country | United States | United States |
| Employees | 8000 | 711 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.4B |
| IPO Year | N/A | 2009 |
| Metric | EQH | ARWR |
|---|---|---|
| Price | $51.53 | $87.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $56.82 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 2.9M | 2.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $43.13 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.20 | $17.22 |
| 52 Week High | $55.24 | $95.49 |
| Indicator | EQH | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 68.83 | 55.26 |
| Support Level | $47.21 | $70.03 |
| Resistance Level | N/A | $87.83 |
| Average True Range (ATR) | 1.49 | 3.89 |
| MACD | 0.13 | 0.41 |
| Stochastic Oscillator | 95.56 | 60.56 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.